Role of Volatile Anesthetics for Hepatic Protection

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00516711
Recruitment Status : Completed
First Posted : August 15, 2007
Last Update Posted : September 15, 2010
Information provided by:
University of Zurich

August 14, 2007
August 15, 2007
September 15, 2010
March 2006
December 2007   (Final data collection date for primary outcome measure)
Blood levels of aspartate aminotransferase (AST), alanine aminotransferase (ALT)
Same as current
Complete list of historical versions of study NCT00516711 on Archive Site
Not Provided
Not Provided
Not Provided
Not Provided
Role of Volatile Anesthetics for Hepatic Protection
Role of Volatile Anesthetics for Hepatic Protection in Ischemia-reperfusion
This study aims to evaluate the attenuation of ischemic-reperfusion injury in the liver after sevoflurane preconditioning. In the presence of sevoflurane, an attenuation of liver injury is hypothesized (diminished increase of liver enzymes, reduced production of inflammatory mediators).
Organ protection; preconditioning; volatile anesthetics; ischemia reperfusion
Not Applicable
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Prevention
Reperfusion Injury
Drug: Sevoflurane
Not Provided
Beck-Schimmer B, Breitenstein S, Urech S, De Conno E, Wittlinger M, Puhan M, Jochum W, Spahn DR, Graf R, Clavien PA. A randomized controlled trial on pharmacological preconditioning in liver surgery using a volatile anesthetic. Ann Surg. 2008 Dec;248(6):909-18. doi: 10.1097/SLA.0b013e31818f3dda.

*   Includes publications given by the data provider as well as publications identified by Identifier (NCT Number) in Medline.
Not Provided
Not Provided
December 2007
December 2007   (Final data collection date for primary outcome measure)

Inclusion Criteria:

  • Older than 18 years of age
  • Patients undergoing liver resection (benign or malignant tumors)

Exclusion Criteria:

  • Laparoscopic liver resection coagulopathy (platelets < 50,000/ml, Quick < 50%)
  • Liver cirrhosis
Sexes Eligible for Study: All
18 Years to 75 Years   (Adult, Senior)
Contact information is only displayed when the study is recruiting subjects
StV 5-2006
Not Provided
Not Provided
Not Provided
University of Zurich
Not Provided
Study Director: 01 Studienregister MasterAdmins UniversitaetsSpital Zuerich
University of Zurich
August 2007

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP